Business Context and Reporting Period
This Form 6-K filing by Novartis AG, dated December 12, 2008, reports on clinical trial updates for the investigational drug Afinitor (everolimus). The filing focuses on data presented at the CTRC-AACR San Antonio Breast Cancer Symposium regarding the treatment of HER2-positive metastatic breast cancer.
Key Financial Metrics
This filing is a current report on clinical developments and does not contain specific financial statements, revenue, profit, cash flow, or debt metrics for the reporting period. Historical context provided in the "About Novartis" section notes that in 2007, the Group's continuing operations achieved net sales of USD 38.1 billion and net income of USD 6.5 billion, with approximately USD 6.4 billion invested in R&D.
Material Changes and Clinical Results
The filing details updated results from two Phase I clinical trials evaluating Afinitor in combination with Herceptin and chemotherapy for patients with documented resistance to Herceptin:
- Study 1 (Afinitor + Herceptin + Taxol): The combination halted tumor growth in 77% of patients. The data demonstrated the first complete response in the trial.
- Study 2 (Afinitor + Herceptin + Navelbine): The combination halted tumor growth in 62% of heavily pretreated patients.
- Next Steps: Based on these results, Novartis announced the initiation of a worldwide Phase III clinical trial program to further evaluate this combination treatment.
Outlook, Risks, and Management Commentary
Management expressed encouragement regarding the potential of Afinitor to reverse Herceptin resistance and restore patient response. The company is committed to evaluating Afinitor in breast cancer and other tumor types. However, the filing includes significant forward-looking statements and risks:
- Regulatory Risk: There is no guarantee that Afinitor will be approved for any oncology indication or become commercially available.
- Clinical Risk: Actual results may vary materially due to unexpected clinical trial data, regulatory delays, or competition.
- Safety Profile: The safety and efficacy profile of Afinitor in oncology has not yet been established. Common grade 3/4 adverse events included neutropenia, stomatitis, and leukopenia.
Key Facts for Investor Verification
- Novartis is initiating a Phase III trial program for Afinitor in combination with Herceptin and chemotherapy for HER2-positive metastatic breast cancer.
- Phase I data showed disease control rates of 77% and 62% in two separate trials involving heavily pretreated, Herceptin-resistant patients.
- Afinitor (everolimus) is currently an investigational drug for oncology; its active ingredient is approved as Certican for transplant rejection prevention.
- There is no guarantee of regulatory approval or future revenue generation from this specific oncology indication.